Head to head
SK hynix vs NVIDIA
Side-by-side on the measures that matter, with a plain-English read. Full detail: SKHY · NVDA
SKHY
SK hynix
103.57-13.11%
1-year price shape — not enough history yet
Quant Rating C · 0/100
vs
NVDA
NVIDIA
125.53-14.01%
1-year price shape — -30% over the period
Quant Rating E · 13/100
1-year performance, rebased to 100
SK hynix edges it on the scoreable measures. SK hynix trades cheapest on trailing earnings.
| SKHY | NVDA | |
|---|---|---|
| Snapshot | ||
| Sector | Semiconductors | -- |
| Last price | 103.57 | 125.53 |
| Change today | -13.11% | -14.01% |
| 1-year return | -- | -30.4% |
| Market cap | $730.35B | $3.03T |
| 52-week range | 102.45 – 199.87 | 124.50 – 243.37 |
| Valuation | ||
| P/E (TTM) | 5.15 | 13.48 |
| P/E percentile, own 5-yr range | 7th | 0th |
| P/B | 3.15 | 11.34 |
| Dividend yield | 0.03% | 0.41% |
| Profitability & growth | ||
| EPS (TTM) | 4.41 | 4.90 |
| Net profit (TTM) | $31.12B | $118.09B |
| Revenue (TTM) | $269.34T | $302.97B |
| Provider revenue period date | 2026-09-29 | 2026-07-25 |
| Revenue growth (YoY) | +327.9% | +105.9% |
| Gross margin | 81.6% | 74.7% |
| Operating margin | 74.5% | 65.2% |
| Net margin | 70.1% | 63.7% |
| Free cash flow (TTM) | $122.29T | $127.01B |
| Provider cash-flow period date | 2026-09-29 | 2026-07-25 |
| Ownership & sentiment | ||
| Institutional ownership | 58.0% | 70.2% |
| Insider activity (12mo) | 0 buy / 0 sell | 13 buy / 36 sell |
| Short interest (% of float) | 0.5% | 1.2% |
| Analyst consensus | 100% buy (8) | 67% buy / 30% hold / 2% sell (43) |
| Analyst price target | $269 (+159%) | $233 (+86%) |
| StockVane view | ||
| StockVane Quant Rating | C (0) | E (13) |
| Company | ||
| Employees | 34,549 | 42,000 |
| Founded | 1949 | 1993 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.